Predicted to enable cholesterol binding activity; lipid transfer activity; and phosphatidylinositol-4,5-bisphosphate binding activity. Predicted to be involved in lipid transport; plasma membrane organization; and protein homotetramerization. Predicted to be extrinsic component of cytoplasmic side of plasma membrane. Predicted to be active in cytosol; intracellular membrane-bounded organelle; and membrane. Predicted to colocalize with lipid droplet. Biomarker of status epilepticus. Human ortholog(s) of this gene implicated in autosomal dominant nonsyndromic deafness 67. Orthologous to human OSBPL2 (oxysterol binding protein like 2); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; bisphenol A; cobalt dichloride.
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of OSBPL2 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of OSBPL2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of OSBPL2 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of OSBPL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of OSBPL2 mRNA more ...
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL2 mRNA